A detailed history of China Universal Asset Management Co., Ltd. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 40,219 shares of ALLO stock, worth $98,938. This represents 0.01% of its overall portfolio holdings.

Number of Shares
40,219
Previous 24,529 63.97%
Holding current value
$98,938
Previous $57,000 96.49%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$2.08 - $3.5 $32,635 - $54,915
15,690 Added 63.97%
40,219 $112,000
Q2 2024

Jul 19, 2024

SELL
$2.23 - $4.38 $17,436 - $34,247
-7,819 Reduced 24.17%
24,529 $57,000
Q1 2024

Apr 29, 2024

BUY
$2.92 - $5.63 $37,612 - $72,520
12,881 Added 66.17%
32,348 $145,000
Q4 2023

May 21, 2024

SELL
$2.28 - $3.5 $29,368 - $45,083
-12,881 Reduced 39.82%
19,467 $62,000
Q4 2023

Jan 23, 2024

BUY
$2.28 - $3.5 $34,587 - $53,095
15,170 Added 353.04%
19,467 $62,000
Q3 2023

May 21, 2024

BUY
$3.17 - $5.96 $7,560 - $14,214
2,385 Added 124.74%
4,297 $13,000
Q3 2023

Oct 30, 2023

BUY
$3.17 - $5.96 $7,560 - $14,214
2,385 Added 124.74%
4,297 $14,000
Q2 2023

May 21, 2024

SELL
$4.53 - $6.74 $208 - $310
-46 Reduced 2.35%
1,912 $9,000
Q2 2023

Jul 27, 2023

SELL
$4.53 - $6.74 $208 - $310
-46 Reduced 2.35%
1,912 $10,000
Q1 2023

May 21, 2024

BUY
$4.92 - $8.21 $2,425 - $4,047
493 Added 33.65%
1,958 $9,000
Q1 2023

Apr 27, 2023

BUY
$4.92 - $8.21 $2,425 - $4,047
493 Added 33.65%
1,958 $10,000
Q4 2022

May 21, 2024

SELL
$5.62 - $11.11 $173,562 - $343,110
-30,883 Reduced 95.47%
1,465 $9,000
Q4 2022

Jan 31, 2023

BUY
$5.62 - $11.11 $663 - $1,310
118 Added 8.76%
1,465 $9,000
Q3 2022

Oct 21, 2022

BUY
$10.32 - $17.28 $13,901 - $23,276
1,347 New
1,347 $15,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $354M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.